Yoshiaki Nakamura Selected Research

Stomach Neoplasms (Stomach Cancer)

6/2022	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
1/2022	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials.
12/2021	Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report.
10/2021	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
3/2021	The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia.
1/2021	A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
1/2020	The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
1/2020	Correction to: Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
1/2020	Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
1/2020	Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshiaki Nakamura Research Topics

Disease

41	Neoplasms (Cancer) 10/2022 - 03/2011
21	Stomach Neoplasms (Stomach Cancer) 06/2022 - 01/2018
19	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 11/2018
11	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2003
8	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2015
5	Microsatellite Instability 01/2022 - 11/2018
5	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 11/2021 - 01/2020
4	Disease Progression 01/2022 - 01/2003
2	Fever (Fevers) 12/2021 - 01/2018
2	Colonic Neoplasms (Colon Cancer) 07/2021 - 01/2017
2	Neutropenia 01/2021 - 12/2019
2	Residual Neoplasm 12/2020 - 01/2019
2	Triple Negative Breast Neoplasms 01/2019 - 07/2012
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 06/2022
1	Lymphatic Metastasis 04/2022
1	Amyloid Plaque 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2022
1	Adenocarcinoma 01/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 12/2021
1	Fatigue 12/2021
1	Hypopituitarism (Sheehan's Syndrome) 12/2021
1	Hypothyroidism 12/2021
1	Cholangiocarcinoma 10/2021
1	Exanthema (Rash) 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Anemia 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Necrosis 12/2020

Drug/Important Bio-Agent (IBA)

14	Circulating Tumor DNAIBA 04/2022 - 11/2018
9	Biomarkers (Surrogate Marker)IBA 04/2022 - 11/2018
7	Immune Checkpoint InhibitorsIBA 09/2022 - 11/2018
6	pembrolizumabIBA 01/2022 - 01/2020
6	Trastuzumab (Herceptin)FDA Link 01/2022 - 12/2010
5	human ERBB2 proteinIBA 01/2022 - 11/2014
5	NivolumabIBA 01/2022 - 01/2019
4	Monoclonal AntibodiesIBA 06/2021 - 01/2019
4	Irinotecan (Camptosar)FDA LinkGeneric 06/2021 - 01/2020
4	Hormones (Hormone)IBA 01/2018 - 01/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 11/2018
3	lenvatinibIBA 01/2022 - 01/2020
3	trifluridine tipiracil drug combinationIBA 07/2021 - 12/2019
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2021 - 02/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2018 - 12/2010
2	trastuzumab deruxtecanIBA 06/2022 - 01/2021
2	regorafenibIBA 01/2022 - 01/2021
2	Formaldehyde (Formol)FDA Link 01/2022 - 01/2018
2	ParaffinIBA 01/2022 - 01/2018
2	pertuzumabIBA 01/2022 - 11/2021
2	Tumor Biomarkers (Tumor Markers)IBA 10/2021 - 07/2021
2	Capecitabine (Xeloda)FDA Link 07/2021 - 02/2019
2	Cell-Free Nucleic AcidsIBA 03/2021 - 12/2019
2	Bevacizumab (Avastin)FDA Link 01/2021 - 12/2019
2	Estrogen ReceptorsIBA 01/2021 - 11/2014
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2020
2	Taxoids (Taxanes)IBA 01/2020 - 09/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2020
2	AnthracyclinesIBA 09/2017 - 03/2012
2	Aromatase InhibitorsIBA 11/2016 - 03/2011
1	Notch ReceptorsIBA 10/2022
1	Pharmaceutical PreparationsIBA 06/2022
1	Amyloid (Amyloid Fibrils)IBA 01/2022
1	CateninsIBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Vitamin D FDA LinkGeneric 01/2022
1	AntibodiesIBA 01/2022
1	hydroxide ionIBA 01/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Hydrocortisone (Cortisol)FDA LinkGeneric 12/2021
1	Docetaxel (Taxotere)FDA Link 12/2021
1	Blood Glucose (Blood Sugar)IBA 12/2021
1	Thyroxine (Levothyroxine)FDA LinkGeneric 12/2021
1	Small Cytoplasmic RNAIBA 11/2021
1	Programmed Cell Death 1 ReceptorIBA 10/2021
1	Panitumumab (Vectibix)FDA Link 06/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	DeoxyuridineIBA 01/2021
1	dUTP pyrophosphataseIBA 01/2021
1	fms-Like Tyrosine Kinase 3IBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	TAS-114IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2020

Therapy/Procedure

28	Therapeutics 01/2022 - 01/2003
15	Drug Therapy (Chemotherapy) 10/2022 - 12/2010
8	Precision Medicine 01/2022 - 09/2018
5	Adjuvant Chemotherapy 12/2021 - 09/2017
3	Immunotherapy 01/2022 - 01/2019
3	Hepatectomy 12/2021 - 05/2002
2	Neoadjuvant Therapy 01/2022 - 01/2019
2	Molecular Targeted Therapy 01/2022 - 01/2022
2	Gastrectomy 12/2021 - 02/2019
2	Genomic Medicine 02/2021 - 09/2018
1	Lymph Node Excision (Lymph Node Dissection) 04/2022
1	Aftercare (After-Treatment) 04/2022
1	Transplantation 01/2021
1	Combination Drug Therapy (Combination Chemotherapy) 01/2020
1	Radiotherapy 01/2020